Bionovo Announces Publication Of Data On Active Compound And Mechanism Of Action For Its Preclinical Cancer Treatment, BN108

Bionovo, Inc. (Nasdaq: BNVI) announced the poster presentation of significant, new data on the nature of the active compound and mechanism of action for its preclinical cancer drug candidate, BN108. The presentation is being made at the 2009 conference of the American Association of Cancer Research (AACR) in Denver.

More: continued here

Filed under: Breast Cancer on April 26th, 2009